Oculis Holding AG

Executive Summary

Oculis Holding AG is a Swiss clinical-stage biopharmaceutical company developing topical, non-invasive treatments for ophthalmic diseases. Its lead product, OCS-01 (dexamethasone nanoparticle eye drops), is being evaluated in Phase 3 trials for diabetic macular edema (DME) and postoperative inflammation. The company also has OCS-02 (anti-TNFα antibody fragment) in development for dry eye disease and uveitis, and OCS-05 for optic neuritis. With a market capitalization of approximately $1.5 billion, Oculis is positioned to address significant unmet needs in ophthalmology. Key near-term value drivers include top-line data from two Phase 3 trials of OCS-01 in DME, expected in Q2 2026, and Phase 2 results for OCS-01 in uveitic macular edema, expected in Q3 2026. Positive outcomes could support regulatory filings and expand the addressable market. The company's focus on topical formulations offers a patient-friendly alternative to intravitreal injections, which could drive adoption if efficacy and safety are confirmed.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 top-line results for OCS-01 in diabetic macular edema70% success
• Q3 2026Phase 2 top-line results for OCS-01 in uveitic macular edema60% success